Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis

Kidney and Blood Pressure Research

Volumn 26, Issue 4, 2003, Pages 240-248

  Stone, John H ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CD40 LIGAND; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LENERCEPT; LIGAND; LIPOPROTEIN LIPASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEMBRANE PROTEIN; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PREDNISONE; PROTEIN P55; PROTEIN P75; RANTES; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANKYLOSING SPONDYLITIS; AORTA ARCH SYNDROME; APOPTOSIS; BEHCET DISEASE; BLOOD VESSEL REACTIVITY; BRONCHITIS; CARTILAGE CELL; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; CROSS LINKING; CYTOKINE RELEASE; DOWN REGULATION; ENDOTHELIUM; FIBROBLAST; GENETIC TRANSCRIPTION; GIANT CELL ARTERITIS; GRANULOMA; HUMAN; IMMUNOCHEMISTRY; IN SITU HYBRIDIZATION; INFECTION; INFLAMMATION; INJECTION SITE; KIDNEY BIOPSY; LISTERIA; MACROPHAGE; MICROVASCULATURE; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SIGNAL TRANSDUCTION; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; TARGET CELL; UPREGULATION; UVEITIS; VASCULITIS; WASTING SYNDROME; WEGENER GRANULOMATOSIS;

ENDOTHELIUM, VASCULAR; HUMANS; MOLECULAR BIOLOGY; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 0141867903     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072991     Document Type: Conference Paper

References (64)

1. Moreland L, Baumgartner S, Schiff M, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147.
2. Moreland L, Schiff M, Baumgartner S, et al: Entenercept therapy in Rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-486.
3. Weinblatt M, Kremer J, Bankhurst A, et al: A trial of Etanercept, a recombinant tumor necrosis factor receptor-Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259.
4. Elliott M, Maini R, Feldman M, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor 44. Arthritis Rheum 1993;36:1681-1690.
5. Elliott M, Maini R, Feldmann M, et al: Randomised double-blind comparison of chimeric monoclonal antibody to tomour necrosis factor R (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110.
6. Elliott M, Maini R, Feldmann M, et al: Repeated therapy with monoclonal antibody to tumor necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-1127.
7. Maini R, Breedveld F, Kalden J, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor v monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563.
8. Stack W, Mann S, Roy A, et al: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997;349:521-524.
9. Targan S, Landers C, Vidrich A, Czaja A: High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995;108:1159-1166.
10. Targan S, Hanauer S, van Deventer S, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Eng J Med 1997;337:1029-1035.
11. Carswell E, Old L, Kassel R, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;75:3666-3670.
12. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A: Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985;161:984-995.
13. Beutler B, Greenwald D, Hulmes J, et al: Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-554.
14. Kawakami M, Pekala P, Lane M, Cerami A: Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 1982;79:912-916.
15. Fisher CJ, Agosti J, Opal S, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-1702.
16. Wherry J, Pennington J, Wenzel R: Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 1993;21:S436-S440.
17. van der Poll T, Lowry S: Tumour necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense? Shock 1995;3:1-12.
18. Agosti J, Fisher C, Opal S, Lowry S, Balk R, Sadoff J: Treatment of patients with sepsis syndrome with soluble TNF receptor (sTNFR). Proc 34th Ann ICAAC 1994;34:65.
19. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, double-blind, multicenter clinical trial. JAMA 1995;273:934-941.
20. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-1725.
21. Tracey K, Vlassara H, Cerami A: Cachectin/tumor necrosis factor. Lancet 1989;1:1126.
22. Banner D, D'Arcy A, Janes W, et al: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. Cell 1993;73:341-345.
23. Beutler B, Bazzoni F: TNF, apoptosis and auto-immunity: A common thread? Blood Cells Molecules Dis 1998;24:216-230.
24. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K: Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor 2. Arthritis Rheum 1996;39:197-203.
25. Jones R, Moreland L: Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999;48:1-4.
26. Carlos T, Harlan J: Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
27. Wegener F: Wegener's granulomatosis: Thoughts and observations of a pathologist. Eur Arch Otorhinolaryngol 1990;247:133-142.
28. Maiti A, Maki G, Johnson P: TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation. Science 1998;282:941-943.
29. Paleolog E, Hunt M, Elliott M, Feldmann M, Maini R, Woody J: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-1091.
30. Tak P, Taylor P, Breedveld F, et al: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-1081.
31. Kindler V, Sappino A, Grau G, Piguet P, Vassalli P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-740.
32. Ludviksson B, Sneller M, Chua K, et al: Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10. J Immun 1998;160:3602-3609.
33. Deguchi Y, Shibata N, Kishimoto S: Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol 1990;81:311-314.
34. Nassonov E, Samsonov M, Tilz G, et al: Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheum 1997;24:666-670.
35. Jonasdottir O, Bendtzen K, Skjodt H, et al: Elevated serum levels of soluble tumore necrosis factor receptors in Wegener's granulomatosis. Arthritis Rheum 1998;41:5116.
36. Noronha I, Kruger C, Andrassy K, Ritz E, Waldherr R: In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993;43:682-692.
37. Falk R, Hogan S, Carey T, Jennette J, Network G: Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 1990;11:656-663.
38. Falk R, Terrell R, Charles L, et al: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-4119.
39. Reumaux D, Vossebeld P, Roos D, Verhoeven A: Effect of tumor necrosis factor-induced inte-grin activation on Fc gamma receptor II-mediated signal transduction: Relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 1995;86:3189-3195.
40. Mayet W, Meyer Zum Buschenfelde K: Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993;94:440-446.
41. Csernok E, Ernst M, Scmitt W, Bainton D, Gross W: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994;98:244-250.
42. Ralston D, Marsh C, Lowe M, Wewers M: Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. J Clin Invest 1997;100:1416-1424.
43. Feldmann M, Elliott M, Woody J, et al: Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.
44. Vassalli P: The pathophysiology of tumor necrosis factors. Ann Rev Immunol 1992;10:411-452.
45. Cunnane G, Doran M, Bresnihan B: Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-363.
46. Gluck T, Linde HJ, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: Report of two cases. Arthritis Rheum 2002;46:2255-2257; author reply 2257.
47. Kremer J: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002;46:2257.
48. Keane J, Gershon S, Wise RP, et al: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
49. Fratazzi C, Arbeit RD, Carini C, Remold HG: Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J Immunol 1997;158:4320-4327.
50. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-3158.
51. Bannworth B, Vernhes J, Schaeverbeke T, Dehais J: The facts about methotrexte in rheumatoid arthritis. Rev Rheum 1995;62:471-473.
52. Peppel K, Crawford D, Beutler B: A tumor necrosis factor receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-1489.
53. Mohler K, Torrance D, Smith C, et al: Soluble tumor necrosis factor receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-1561.
54. Sander O, Rau R, vanRiel P, et al: Neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of a European phase II trial. Arthritis Rheum 1996;39(suppl 9):S242.
55. Hasler F, van de Putte L, Dumont E, et al: Safety and efficacy of the neutralization by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis exposed to a single dose. Arthritis Rheum 1996;39(9 suppl):S243.
56. Hasler F, van de Putte L, Baudin M, et al: Chronic TNF neutralization (up to 1 year) by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis: results of an open-label extension of a double-blind single dose phase I study. Arthritis Rheum 1996;39(suppl 9):S243.
57. Stone JH, Uhlfelder ML, Hellmann DB, Bedocs N-M, Crook S, Hoffman GS: Etanercept combined with conventional treatment in Wegener's granulomatosis: A six month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149-1154.
58. Stone JH, Hoffman GS, Merkel PA, et al: A disease-specific vasculitis activity index for Wegener's granulomatosis: Modification of The Birmingham Vasculitis Activity Score. Arthritis Rheum 2001;44:912-920.
59. Langford C, Talar-Williams C, Barron K, McCabe K, Sneller M: Phase I/II trial of etanercept in Wegener's granulomatosis: Safety and preliminary experience. Arthritis Rheum 2000;43:S163.
60. The WGET Research Group: Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002;23:450-468.
61. The WGET Research Group: Limited versus severe Wegener's granulomatosis: Baseline data from the Wegener's granulomatosis etanercept trial (WGET). Arthritis Rheum 2003; in press.
62. Bartolucci P, Ramanoelina J, Cohen P, et al: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology (Oxf) 2002;41:1126-1132.
63. Lamprecht P, Voswinkel J, Lilienthal T, et al: Effectiveness of TNF-alpha blockade with in-fliximab in refractory Wegener's granulomatosis. Rheumatology (Oxf) 2002;41:1303-1307.
64. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I: Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. Arthritis Rheum. 2001;44:2933-2935.